Fulcrum Therapeutics EBIT

Fulcrum Therapeutics (FULC) currently reports a EBIT of $-94M as of June 2026. That compares with $-85M in the prior-year period — down 10.5% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Fulcrum Therapeutics's EBIT history and peer comparisons.

Fulcrum Therapeutics's EBIT decreased from $-85M to $-94M — a 10.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Fulcrum Therapeutics's EBIT of $-94M is lower than the Healthcare sector average of $22B. That is roughly 100.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Fulcrum Therapeutics reported $-94M in EBIT as of June 2026. That compares with $-85M in the prior-year period — down 10.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-94M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Fulcrum Therapeutics, and consider following FULC for alerts when major investors trade the stock.